Next Article in Journal
Effectiveness of an Intervention of Dietary Counseling for Overweight and Obese Pregnant Women in the Consumption of Sugars and Energy
Next Article in Special Issue
Magnesium: A Magic Bullet for Cardiovascular Disease in Chronic Kidney Disease?
Previous Article in Journal
Free Fatty Acids’ Level and Nutrition in Critically Ill Patients and Association with Outcomes: A Prospective Sub-Study of PermiT Trial
Previous Article in Special Issue
Dietary Protein, Kidney Function and Mortality: Review of the Evidence from Epidemiological Studies
Open AccessReview

Folic Acid and Vitamin B12 Administration in CKD, Why Not?

Department of Experimental Diagnostic and Specialty Medicine (DIMES), Nephrology, Dialysis and Renal Transplant Unit, S. Orsola Hospital, University of Bologna, 40138 Bologna, Italy
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(2), 383; https://doi.org/10.3390/nu11020383
Received: 29 January 2019 / Revised: 9 February 2019 / Accepted: 11 February 2019 / Published: 13 February 2019
Patients affected by chronic kidney disease (CKD) or end-stage renal disease (ESRD) experience a huge cardiovascular risk and cardiovascular events represent the leading causes of death. Since traditional risk factors cannot fully explain such increased cardiovascular risk, interest in non-traditional risk factors, such as hyperhomocysteinemia and folic acid and vitamin B12 metabolism impairment, is growing. Although elevated homocysteine blood levels are often seen in patients with CKD and ESRD, whether hyperhomocysteinemia represents a reliable cardiovascular and mortality risk marker or a therapeutic target in this population is still unclear. In addition, folic acid and vitamin B12 could not only be mere cofactors in the homocysteine metabolism; they may have a direct action in determining tissue damage and cardiovascular risk. The purpose of this review was to highlight homocysteine, folic acid and vitamin B12 metabolism impairment in CKD and ESRD and to summarize available evidences on hyperhomocysteinemia, folic acid and vitamin B12 as cardiovascular risk markers, therapeutic target and risk factors for CKD progression. View Full-Text
Keywords: cardiovascular disease; chronic kidney disease; end-stage renal disease; hyperhomocysteinemia; folic acid; vitamin B12 cardiovascular disease; chronic kidney disease; end-stage renal disease; hyperhomocysteinemia; folic acid; vitamin B12
Show Figures

Figure 1

MDPI and ACS Style

Capelli, I.; Cianciolo, G.; Gasperoni, L.; Zappulo, F.; Tondolo, F.; Cappuccilli, M.; La Manna, G. Folic Acid and Vitamin B12 Administration in CKD, Why Not? Nutrients 2019, 11, 383.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop